Research programme: CNS therapeutics - Eli Lilly/NeuroSearch

Drug Profile

Research programme: CNS therapeutics - Eli Lilly/NeuroSearch

Alternative Names: CNS therapeutics - Eli Lilly/NsDiscovery

Latest Information Update: 04 Dec 2013

Price : $50

At a glance

  • Originator NeuroSearch
  • Class
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 28 Sep 2011 Preclinical development is ongoing in USA
  • 11 Jan 2011 NeuroSearch announces restructure where all ion channel drug discovery activities and existing alliances will be organised in a new division, NsDiscovery
  • 17 Feb 2009 Early research in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top